Search results

The Biosciences group of researchers at ANSTO supports the development and translation of radiopharmaceuticals to improve human health.

ANSTO is celebrating the official opening of HIFAR, Australia’s first nuclear reactor, sixty-five years ago.

Excellent radiolabelling facilities and the operation of OPAL, a world-class multi-purpose nuclear reactor, enable ANSTO to produce a large range of radioisotopes for Australian researchers in both radiopharmaceutical and environmental areas.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

System includes a vibrating-sample magnetometer, AC susceptibility, heat capacity and resistivity measurement capability.  

The Graduate Institute is part of ANSTO’s Innovation Precinct and links all graduates together to create a network of Australia’s brightest young minds focused on the future.

German ambassador visits to see a ‘sparrow’ being assembled.

Four annual awards in neutron scattering were announced at Australian Neutron Beam Users Group (ANBUG) and AINSE Neutron Scattering Symposium (AANSS) to individuals with strong links to ANSTO

ANSTO manufacture and supply a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.

An opportunity to take an unforgettable journey and explore ANSTO science virtually at the atomic scale for National #scienceweek

ANSTO's Chief Nuclear Officer shares insights on the safe management of Australia's nuclear waste.

The shutdown of a nuclear reactor can be done manually by an operator following a well-established operating procedure.